APA (7th ed.) Citation

G, G., L, K., J, d. S., SL, H., J, O., H, K., . . . JS, W. (2022). Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials. European journal of neurology, 29(4), 1238. https://doi.org/10.1111/ene.14823

Chicago Style (17th ed.) Citation

G, Giovannoni, Kappos L, de Seze J, Hauser SL, Overell J, Koendgen H, Manfrini M, Wang Q, and Wolinsky JS. "Risk of Requiring a Walking Aid After 6.5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis: Data from the OPERA I and OPERA II Trials." European Journal of Neurology 29, no. 4 (2022): 1238. https://doi.org/10.1111/ene.14823.

MLA (9th ed.) Citation

G, Giovannoni, et al. "Risk of Requiring a Walking Aid After 6.5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis: Data from the OPERA I and OPERA II Trials." European Journal of Neurology, vol. 29, no. 4, 2022, p. 1238, https://doi.org/10.1111/ene.14823.